REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
REGENXBIO Inc.NASDAQ: RGNX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2026 selling, general & admin of $21.31M rose 4.7% year over year, behind the +6.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.
Context
- Selling, general & admin amounted to 48.6% of revenue in FY2025, down 43.3 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $100.51M (+21.3%) for the fiscal year ending Dec 2026, a step up from the +8.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $21.31M-4.8% QoQ
- Last fiscal yearDec 2025
- $82.86M+8.1% YoY
- LTMMar 2026
- $83.82M+6.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 82.86M USD
- Year-over-year change
- +8.1%
- 4-year CAGR
- +1.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82.86M | +8.1% |
| FY2024 | 2024-12-31 | 76.62M | -13.4% |
| FY2023 | 2023-12-31 | 88.49M | +3.8% |
| FY2022 | 2022-12-31 | 85.28M | +7.5% |
| FY2021 | 2021-12-31 | 79.33M | — |
Selling, General & Admin vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's LTM Mar 2026 selling, general & admin of $83.82M is the 2nd highest of the 10 companies compared; the peer median is $47.81M.
- Its year-over-year change of +6.5% is the 5th highest of 10, against a peer median of -2.1%.
- Selling, general & admin amounts to 95.4% of revenue for RGNX, versus a peer median of 99.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $84.93M | +155.9% | +13.5% | 99.1% | |
| LTM Mar 2026 | $83.82M | +6.5% | -1.0% | 95.4% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Mar 2026 | $71.65M | +50.0% | +6.1% | 396.0% | |
| LTM Mar 2026 | $52.46M | -2.3% | +4.4% | 65.8% | |
| LTM Mar 2026 | $47.81M | -5.9% | +14.2% | 54.2% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $36.17M | -2.1% | +6.6% | 99.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
| LTM Mar 2026 | $29.24M | +9.4% | -8.0% | 654.9% | |
| Peer median (excluding RGNX) | $47.81M | -2.1% | +10.3% | 99.1% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M |
| Cost of Revenue | 51.83M | 54.55M | 37.21M | 33.57M | 20.3M |
| Gross Profit | 418.51M | 58.18M | 53.03M | 49.76M | 150.14M |
| Gross Margin | 89.0% | 51.6% | 58.8% | 59.7% | 88.1% |
| Research & Development | 181.44M | 242.45M | 232.27M | 208.52M | 228.3M |
| Selling, General & Admin | 79.33M | 85.28M | 88.49M | 76.62M | 82.86M |
| Operating Expenses | 258.53M | 321.06M | 321.16M | 283.11M | 311.34M |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| EBITDA | 177.09M | (244.24M) | (239.46M) | (198.23M) | (133.26M) |
| EBITDA Margin | 37.7% | -216.7% | -265.4% | -237.9% | -78.2% |
| Operating Income | 159.98M | (262.88M) | (268.13M) | (233.35M) | (161.2M) |
| Operating Margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Interest Income | 719K | 342K | 25K | 174K | 12.27M |
| Interest Expense | 26.28M | 23.25M | 6.86M | 12.66M | 45.01M |
| Other Income / Expenses | (18.73M) | (17.53M) | 4.48M | 6.24M | (32.68M) |
| Income Before Tax | 141.25M | (280.41M) | (263.65M) | (227.1M) | (193.88M) |
| Pre-Tax Margin | 30.0% | -248.8% | -292.2% | -272.5% | -113.8% |
| Income Tax Expense | 13.41M | (84K) | (152K) | 0 | 0 |
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Net Margin | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| EPS (Basic) | 3.01 | (6.50) | (6.02) | (4.59) | (3.76) |
| EPS (Diluted) | 2.91 | (6.50) | (6.02) | (4.59) | (3.76) |
| Weighted Avg Shares | 42.44M | 43.15M | 43.73M | 49.51M | 51.57M |
| Weighted Avg Shares (Diluted) | 43.91M | 43.15M | 43.73M | 49.51M | 51.57M |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.